Cargando…

Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas

PURPOSE: Adenocarcinomas of the esophagus (AEG) and stomach (AS) are among the most common cancers worldwide. Novel markers for risk stratification and guiding treatment are strongly needed. Activin is a multi-functional cytokine with context specific pro- and anti-tumorigenic effects. We aimed to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Staudacher, J. J., Arnold, Alexander, Kühl, A. A., Pötzsch, M., Daum, S., Winterfeld, M., Berg, E., Hummel, M., Rau, B., Stein, U., Treese, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446826/
https://www.ncbi.nlm.nih.gov/pubmed/36064338
http://dx.doi.org/10.1186/s12885-022-10016-5
_version_ 1784783725591003136
author Staudacher, J. J.
Arnold, Alexander
Kühl, A. A.
Pötzsch, M.
Daum, S.
Winterfeld, M.
Berg, E.
Hummel, M.
Rau, B.
Stein, U.
Treese, C.
author_facet Staudacher, J. J.
Arnold, Alexander
Kühl, A. A.
Pötzsch, M.
Daum, S.
Winterfeld, M.
Berg, E.
Hummel, M.
Rau, B.
Stein, U.
Treese, C.
author_sort Staudacher, J. J.
collection PubMed
description PURPOSE: Adenocarcinomas of the esophagus (AEG) and stomach (AS) are among the most common cancers worldwide. Novel markers for risk stratification and guiding treatment are strongly needed. Activin is a multi-functional cytokine with context specific pro- and anti-tumorigenic effects. We aimed to investigate the prognostic role of activin tumor protein expression in AEG/ASs. METHODS: Tissue from a retrospective cohort of 277 patients with AEG/AS treated primarily by surgery at the Charité - Universitätsmedizin Berlin was collected and analyzed by immunohistochemistry using a specific antibody to the activin homodimer inhibin beta A. Additionally, we evaluated T-cell infiltration and PD1 expression as well as expression of PD-L1 by immunohistochemistry as possible confounding factors. Clinico-pathologic data were collected and correlated with activin protein expression. RESULTS: Out of 277 tumor samples, 72 (26.0%) exhibited high activin subunit inhibin beta A protein expression. Higher expression was correlated with lower Union for International Cancer Control (UICC) stage and longer overall survival. Interestingly, activin subunit expression correlated with CD4(+) T-cell infiltration, and the correlation with higher overall survival was exclusively seen in tumors with high CD4(+) T-cell infiltration, pointing towards a role of activin in the tumor immune response in AEG/ASs. CONCLUSION: In our cohort of AEG/AS, higher activin subunit levels were correlated with longer overall survival, an effect exclusively seen in tumors with high CD4(+) cell infiltration. Further mechanistic research is warranted discerning the exact effect of this context specific cytokine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10016-5.
format Online
Article
Text
id pubmed-9446826
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-94468262022-09-07 Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas Staudacher, J. J. Arnold, Alexander Kühl, A. A. Pötzsch, M. Daum, S. Winterfeld, M. Berg, E. Hummel, M. Rau, B. Stein, U. Treese, C. BMC Cancer Research Article PURPOSE: Adenocarcinomas of the esophagus (AEG) and stomach (AS) are among the most common cancers worldwide. Novel markers for risk stratification and guiding treatment are strongly needed. Activin is a multi-functional cytokine with context specific pro- and anti-tumorigenic effects. We aimed to investigate the prognostic role of activin tumor protein expression in AEG/ASs. METHODS: Tissue from a retrospective cohort of 277 patients with AEG/AS treated primarily by surgery at the Charité - Universitätsmedizin Berlin was collected and analyzed by immunohistochemistry using a specific antibody to the activin homodimer inhibin beta A. Additionally, we evaluated T-cell infiltration and PD1 expression as well as expression of PD-L1 by immunohistochemistry as possible confounding factors. Clinico-pathologic data were collected and correlated with activin protein expression. RESULTS: Out of 277 tumor samples, 72 (26.0%) exhibited high activin subunit inhibin beta A protein expression. Higher expression was correlated with lower Union for International Cancer Control (UICC) stage and longer overall survival. Interestingly, activin subunit expression correlated with CD4(+) T-cell infiltration, and the correlation with higher overall survival was exclusively seen in tumors with high CD4(+) T-cell infiltration, pointing towards a role of activin in the tumor immune response in AEG/ASs. CONCLUSION: In our cohort of AEG/AS, higher activin subunit levels were correlated with longer overall survival, an effect exclusively seen in tumors with high CD4(+) cell infiltration. Further mechanistic research is warranted discerning the exact effect of this context specific cytokine. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-022-10016-5. BioMed Central 2022-09-05 /pmc/articles/PMC9446826/ /pubmed/36064338 http://dx.doi.org/10.1186/s12885-022-10016-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Staudacher, J. J.
Arnold, Alexander
Kühl, A. A.
Pötzsch, M.
Daum, S.
Winterfeld, M.
Berg, E.
Hummel, M.
Rau, B.
Stein, U.
Treese, C.
Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
title Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
title_full Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
title_fullStr Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
title_full_unstemmed Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
title_short Prognostic impact of activin subunit inhibin beta A in gastric and esophageal adenocarcinomas
title_sort prognostic impact of activin subunit inhibin beta a in gastric and esophageal adenocarcinomas
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446826/
https://www.ncbi.nlm.nih.gov/pubmed/36064338
http://dx.doi.org/10.1186/s12885-022-10016-5
work_keys_str_mv AT staudacherjj prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT arnoldalexander prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT kuhlaa prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT potzschm prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT daums prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT winterfeldm prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT berge prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT hummelm prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT raub prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT steinu prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas
AT treesec prognosticimpactofactivinsubunitinhibinbetaaingastricandesophagealadenocarcinomas